Recombinant multi-species IL-7/IL7 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-7/IL7 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL7 is found to be a cofactor for V(D)J rearrangement of the T cell receptor beta (TCRB) during early T cell development. This cytokine can be produced locally by intestinal epithelial and epithelial goblet cells, and may serve as a regulatory factor for intestinal mucosal lymphocytes. IL7 plays an essential role in lymphoid cell survival, and in the maintenance of naive and memory T cells. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional splice variants have been described but their presence in normal tissues has not been confirmed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can be a potent inducer of proinflammatory cytokines and chemokines which may defend against the infection, but may also mediate destructive lung injury. Elevated serum IL7 levels, together with several other circulating cytokines and chemokines, has been found to be associated with the severity of Coronavirus Disease 19 (COVID-19). [provided by RefSeq, Jul 2020]
The Alternative Names of target: A630026I06Rik,IL-7,IL7,IMD130,Il-7,Il7,Interleukin-7,hlb368
Go
to IL-7/IL7 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T35232-Ag-1/ GM-Tg-hg-T35232-Ag-2 | Human IL-7/IL7 protein | Human |
| GM-Tg-rg-T35232-Ag-1/ GM-Tg-rg-T35232-Ag-2 | Rat IL-7/IL7 protein | Rat |
| GM-Tg-mg-T35232-Ag-1/ GM-Tg-mg-T35232-Ag-2 | Mouse IL-7/IL7 protein | Mouse |
| GM-Tg-cynog-T35232-Ag-1/ GM-Tg-cynog-T35232-Ag-2 | Cynomolgus/Rhesus macaque IL-7/IL7 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T35232-Ag-1/ GM-Tg-felg-T35232-Ag-2 | Feline IL-7/IL7 protein | Feline |
| GM-Tg-cang-T35232-Ag-1/ GM-Tg-cang-T35232-Ag-2 | Canine IL-7/IL7 protein | Canine |
| GM-Tg-bovg-T35232-Ag-1/ GM-Tg-bovg-T35232-Ag-2 | Bovine IL-7/IL7 protein | Bovine |
| GM-Tg-equg-T35232-Ag-1/ GM-Tg-equg-T35232-Ag-2 | Equine IL-7/IL7 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-T35232-Ag-1/ GM-Tg-hg-T35232-Ag-2;
GM-Tg-rg-T35232-Ag-1/ GM-Tg-rg-T35232-Ag-2;
GM-Tg-mg-T35232-Ag-1/ GM-Tg-mg-T35232-Ag-2; GM-Tg-cynog-T35232-Ag-1/ GM-Tg-cynog-T35232-Ag-2; GM-Tg-felg-T35232-Ag-1/ GM-Tg-felg-T35232-Ag-2; GM-Tg-cang-T35232-Ag-1/ GM-Tg-cang-T35232-Ag-2; GM-Tg-bovg-T35232-Ag-1/ GM-Tg-bovg-T35232-Ag-2; GM-Tg-equg-T35232-Ag-1/ GM-Tg-equg-T35232-Ag-2 |
| Products Name | IL-7/IL7 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | IL-7/IL7 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-7/IL7 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.